[
  {
    "path": "hema/07-08-2022/",
    "title": "Fri Jul 08 2022",
    "description": "99 articles - From Friday Jul 01 2022 to Friday Jul 08 2022",
    "author": [],
    "date": "2022-07-08",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nLetters&Replies\r\nOthers\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#rjwwacpbdx .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#rjwwacpbdx .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rjwwacpbdx .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#rjwwacpbdx .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#rjwwacpbdx .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rjwwacpbdx .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rjwwacpbdx .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rjwwacpbdx .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#rjwwacpbdx .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#rjwwacpbdx .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#rjwwacpbdx .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#rjwwacpbdx .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rjwwacpbdx .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rjwwacpbdx .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#rjwwacpbdx .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#rjwwacpbdx .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rjwwacpbdx .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#rjwwacpbdx .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rjwwacpbdx .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rjwwacpbdx .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rjwwacpbdx .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rjwwacpbdx .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#rjwwacpbdx .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rjwwacpbdx .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rjwwacpbdx .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rjwwacpbdx .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rjwwacpbdx .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rjwwacpbdx .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#rjwwacpbdx .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#rjwwacpbdx .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#rjwwacpbdx .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#rjwwacpbdx .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#rjwwacpbdx .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#rjwwacpbdx .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#rjwwacpbdx .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood Adv\r\n    International Consensus Statement on the Management of Cardiovascular Risk of Bruton's Tyrosine Kinase Inhibitors in CLL.\r\nOptimizing heart failure, arrhythmia, and hypertension control will likely improve tolerance and maintenance of BTKi therapy. However, additional studies are needed to identify the most optimal strategy for these drugs.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper.\r\nPatient values and preferences, balancing the risk of bleeding against thromboembolism, are reviewed, and the prognostic implications of bleeding are discussed. We propose consensus statements that may help to define evidence gaps and assist in everyday clinical practice.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#apofbondlq .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#apofbondlq .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#apofbondlq .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#apofbondlq .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#apofbondlq .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#apofbondlq .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#apofbondlq .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#apofbondlq .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#apofbondlq .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#apofbondlq .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#apofbondlq .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#apofbondlq .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#apofbondlq .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#apofbondlq .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#apofbondlq .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#apofbondlq .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#apofbondlq .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#apofbondlq .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#apofbondlq .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#apofbondlq .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#apofbondlq .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#apofbondlq .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#apofbondlq .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#apofbondlq .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#apofbondlq .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#apofbondlq .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#apofbondlq .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#apofbondlq .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#apofbondlq .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#apofbondlq .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#apofbondlq .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#apofbondlq .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#apofbondlq .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#apofbondlq .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#apofbondlq .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood Adv\r\n    ICH in patients with primary or metastatic brain cancer treated or not with anticoagulants: a systematic review and meta-analysis.\r\nPatients with primary brain cancer have an increased risk of ICH during anticoagulation. DOACs are associated with a lower risk of ICH than LMWH.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Association of FLT3-ITD length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials.\r\n  There was no significant increase in the overall risk of VTE in patients treated with ICIs;  however, special attention should be given to the risk of VTE in PD-1/PD-L1 inhibitor and CTLA-4 inhibitor combination therapy and PE in lung cancer patients. PD-L1 inhibitors were associated with a significant increase in ATE.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#wzckdgwpoa .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#wzckdgwpoa .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wzckdgwpoa .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#wzckdgwpoa .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#wzckdgwpoa .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#wzckdgwpoa .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wzckdgwpoa .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#wzckdgwpoa .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#wzckdgwpoa .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#wzckdgwpoa .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#wzckdgwpoa .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#wzckdgwpoa .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#wzckdgwpoa .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#wzckdgwpoa .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#wzckdgwpoa .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#wzckdgwpoa .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#wzckdgwpoa .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#wzckdgwpoa .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#wzckdgwpoa .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#wzckdgwpoa .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#wzckdgwpoa .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#wzckdgwpoa .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#wzckdgwpoa .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#wzckdgwpoa .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wzckdgwpoa .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#wzckdgwpoa .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wzckdgwpoa .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#wzckdgwpoa .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#wzckdgwpoa .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#wzckdgwpoa .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#wzckdgwpoa .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#wzckdgwpoa .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#wzckdgwpoa .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#wzckdgwpoa .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#wzckdgwpoa .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    BRD4 Degradation Blocks Expression of MYC and Multiple Forms of Stem Cell Resistance in Ph+ Chronic Myeloid Leukemia.\r\nFinally, dBET6 was found to suppress the in vitro survival of CML LSC and their engraftment in NSG mice. Together, targeting of BRD4 and MYC through BET degradation sensitizes CML cells against BCR::ABL1 TKI and is a potent approach to overcome multiple forms of drug resistance in CML LSC.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.\r\n Following progression from maintenance olaparib in the recurrent setting, the efficacy of platinum-based subsequent chemotherapy seems to be reduced in BRCA1/2 mutated patients with PSROC compared to patients not previously receiving PARPi. The optimal strategy for patients who relapse after PARP inhibitors is an area of ongoing research.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTherapeutic drug monitoring based precision dosing of oral targeted therapies in oncology: a prospective multicentre study.\r\n Pharmacokinetically guided dose optimization of oral targeted therapies was feasible in clinical practice and reduced the proportion of underexposed patients considerably.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Abnormal Metaphase Cytogenetics Predicts Venous Thromboembolism in Myeloma: Derivation and Validation of the PRISM Score.\r\nRisk of VTE increased significantly with increasing score in both derivation and external validation datasets, with the sHR per 1-point increase being 1.28 (95% CI, 1.19-1.39;  p<0.001) and 1.23 (95% CI, 1.07-1.41;  p=0.004) respectively. While PRISM score can guide clinicians in identifying patients at a high risk of VTE, additional external validation is necessary for incorporation into routine clinical practice.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDiagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.\r\nThere have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update which includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEarly cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.\r\nA baseline difference of involved/uninvolved free light chains (dFLC) >50 mg/L (OR 0.21, P=0.024) and a bone marrow plasma cell infiltrate >10% (OR 0.23, P=0.040) were negative predictors of 90-day cardiac response. Early cardiac responses are rare but possible in stage IIIb AL amyloidosis and translate in longer survival.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes.\r\nGenetic testing should be part of the diagnostic evaluation for al patients with SAA to tailor therapeutic regimens. Carriers of a pathogenic variant in an IBMFS gene can follow HCT regimens for acquired SAA.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow I Treat and Prevent COVID-19 in Patients with Hematologic Malignancies and Recipients of Cellular Therapies.\r\nSelection and administration of the best treatment options are based on host factors;  virus factors, including circulating SARS-CoV-2 variants;  and therapeutic considerations, including the clinical efficacy, availability, and practicality of treatment and its associated side effects, including drug-drug interactions. In this paper, we discuss how we approach managing COVID-19 in patients with hematologic malignancies and recipients of HCT and cell therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHuman complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B cell malignancy.\r\nSystematic single-cell-omic analyses in peripheral blood mononuclear cells (PBMCs) revealed an environment that promotes lymphomagenesis with accumulation of naÃ¯ve B cells (enriched for oncogenic signatures - MYC, JAK1), exhausted CD4+ T cells, impaired T follicular helper cells, and aberrant CD8+ T cells. This work highlights the pleiotropic role of human NFAT1, will empower the diagnosis of additional patients with NFAT1 deficiency, and further define the detrimental effects associated with long-term use of calcineurin inhibitors.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIbrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse.\r\nThe addition of intrathecal chemotherapy to systemic CNS directed therapy was not associated with superior OS (p=0.502), as the morphological variant (classical versus others, p=0.118). Ibrutinib was associated with superior survival compared to BBB penetrating chemotherapy in patients with CNS relapse of MCL, and should be considered as a therapeutic option.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImmune Complications and their Management in Inherited and Acquired Bleeding Disorders.\r\nITI serves as an important proof-of-principle that antigen-specific immune tolerance can be achieved in humans through repeated antigen administration, even in the absence of immune suppression. Finally, novel immunotherapy approaches that are still in pre-clinical phase such as cellular (for instance regulatory T cell) immunotherapies, gene therapy, and oral antigen administration are discussed.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nKIR-Favorable TCR-aÃŸ/CD19-Depleted Haploidentical HCT in Children with ALL/AML/MDS: Primary Analysis of PTCTC ONC1401.\r\nThis prospective, multicenter study showed improved outcomes using TCR-aÃŸ/CD19-depleted haploidentical donors using RTC for children with acute leukemia and MDS;  randomized trials comparing this approach with matched unrelated donors are warranted (ClinicalTrials. gov NCT02646839).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey.\r\nOverall, although CNB accurately diagnoses lymphoma in most instances, it increases the risk of erroneous or non-definitive conclusions. This large-scale survey also emphasizes the need for systematic expert review in cases of lymphoma suspicion, especially in those sampled by CNB.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T for Richter transformed DLBCL.\r\nGene expression profiling revealed upregulation of exhaustion markers on (CAR) T-cells and decreased expression of genes involved in STAT signalling and inflammatory response. In conclusion, this case highlights the complex nature of CAR-T-related hematological toxicity and introduces oligoclonal (CAR) T-cell expansion as a potential contributing pathophysiologic mechanism.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPhysioxia induced Downregulation of Tet2 in Hematopoietic Stem Cells contributes to Enhanced Self-renewal.\r\nThe lack of response to changes in oxygen tension in Tet2-/- HSCs was associated with similar changes in self-renewal and quiescence genes among WT-HSC-physioxia, Tet2-/-HSC-physioxia and Tet2-/-HSC-air. We define a novel molecular program involving Tet2 in regulating HSCs under physioxia.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRace, Rituximab, and Relapse in TTP.\r\nBlack patients may require closer monitoring, earlier retreatment, and alternative immunosuppression following rituximab treatment. How race, racism, and the social determinants of health contribute to the disparity in relapse risk in iTTP deserve further study.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nStructures of VWF tubules before and after concatemerization reveal a mechanism of disulfide bond exchange.\r\nIn addition, the structures reveal disulfide states prior to and after disulfide bond-mediated concatemerization. The structures and proposed assembly mechanism provide a foundation to rationalize VW disease-causing mutations.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTranslation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis.\r\nGly40Ala) rescued UBA1b levels to those of canonical mutations. We conclude that regulation of residual UBA1b translation is fundamental to the pathogenesis of VEXAS syndrome and contributes to disease prognosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors.\r\nSubsequent gene module analyses indicated that gilteritinib responsiveness was associated with lymphocyte differentiation and myeloid leukocyte activation, whereas unresponsiveness to gilteritinib was associated with upregulation of cell-cycle, DNA/RNA metabolic processes, and protein translation. Collectively, these findings indicate a crucial role for microenvironment-mediated factors modulated by BMX in the escape from targeted therapy and have implications for the development of novel therapeutic interventions to restore sensitivity to gilteritinib.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinical Characteristics and Outcomes of IgD Myeloma: Experience across UK National Trials.\r\nSurvival outcomes for IgD myeloma have significantly improved and are now comparable to other myeloma types due to earlier diagnosis, novel therapies and improved supportive care. (Myeloma IX International Standard Randomised Controlled Trial Number: 68454111, Myeloma XI International Standard Randomised Controlled Trial Number: 49407852).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEfficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura.\r\nAt least one adverse event (AE) occurred in 30% of the patients, usually gastrointestinal toxicity, prompting treatment interruption in 14% of treated patients. Thus, azathioprine proved to be effective in terms of clinical relapse prevention, attainment of a durable ADAMTS13 remission, with infrequent and relatively mild AEs.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEvaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.\r\nThese data suggest that management of older individuals with FL may not be fully informed by recent clinical trials. Moreover, liberalizing stage and platelet criteria might expand the eligible population and allow for quicker trial accrual without impacting outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGRK2 regulates ADP signaling in platelets via P2Y1 and P2Y12.\r\nFinally, we show that GRK2 binds to endogenous GÃŸ subunits during platelet activation. Collectively, these results show that GRK2 regulates ADP signaling via P2Y1 and P2Y12, interacts with GÃŸ, and functions as a signaling hub in platelets for modulating the hemostatic response to injury.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHigh early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.\r\nReduced response rates to induction chemotherapy and leukemic clone persistence suggest a need for different treatment intensities and/or modalities in Black AYA patients with AML. Higher early death rates suggest a delay in diagnosis and treatment, calling for systematic changes to patient care.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHMGA2 expression defines a subset of AML with immature transcriptional signature and vulnerability to G2/M inhibition.\r\nAccordingly, small molecules that target G2/M proteins were preferentially active in vitro and in vivo on HMGA2+ AML specimens. Together, our findings suggest that HMGA2 is a key functional determinant in AML and is associated with stem cell features, G2/M status and related drug sensitivity.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nICOS ImmunoPET Enables Visualization of Activated T Cells and Early Diagnosis of Murine Acute Gastrointestinal GvHD.\r\nImportantly, we demonstrate that the 89Zr-DFO-ICOS mAb PET tracer does not affect GvHD pathogenesis or the graft-versus-tumor (GvT) effect of the transplant procedure. Our data identify ICOS immunoPET as a promising strategy for early GvHD diagnosis prior to the appearance of clinical symptoms.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImproved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant.\r\nOne-year non-relapse mortality was greater after ATG-based prophylaxis: (38%, 23% - 52%;  versus 16%, 9% - 25%;  P < 0.001). In summary, PTCy based prophylaxis resulted in superior GRFS and OS in recipients of MMUD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIn vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies.\r\nFor instance, we identified Fermt3, a master regulator of integrin signaling, as an in vivo-specific dependency with high prognostic relevance. Overall, we demonstrate an experimental and computational pipeline for genome-wide functional screens in vivo in AML and provide a genome-wide resource of essential drivers of leukemic growth in vivo.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlatelet activation and partial desensitization are associated with viral xenophagy in patients with severe COVID-19.\r\nThey had large LC3-positive structures and increased levels of LC3II with a co-localization of LC3 and Spike, suggesting that platelets can digest SARS-CoV-2 material by xenophagy in critically ill patients. Altogether, these data show that during severe COVID-19, platelets get activated, become partly desensitized, and develop a selective autophagy response.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nReduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: a LOC-network study.\r\nThe results of the 36-month neuropsychological follow-up for a subset of patients appeared quite reassuring, with most patients exhibiting maintenance of or improvements in their baseline conditions. Our results, combined with phase II study results, support the use of rdWBRT instead of sdWBRT as a consolidation treatment option in <60-year-old patients showing CR after induction treatment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSafety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.\r\nThese data indicate that the transplantation of available stem cell products for post-CAR-T cytopenias is clinically feasible, safe and efficacious. Further studies are needed to assess, whether a pre-emptive collection of stem cells can be justified in selected high-risk patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSiltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.\r\nSiltuximab treatment prolongs PFS, rapidly improves symptomatology, and provides meaningful clinical benefit despite some laboratory tests and enlarged lymph nodes taking months to normalize in treatment responders. These data support the continued front-line use of siltuximab for iMCD, as recommended by international guidelines.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease.\r\nThese data provide the basis for a phase IIb/III trial in such patients. This trial is registered at as NCT04677803.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells.\r\nWe also find that enhancer-regulated APOBEC3 expression contributes to replication stress in malignant B cells. In total we demonstrate a novel mechanism for BTKi suppression of APOBEC3 expression via direct enhancer regulation in an NFATc1-dependent manner, implicating BCR signaling as a potential regulator of leukemic genomic instability.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNext-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.\r\nOur data indicate that anti-CD19 FasT CAR-T shows promising early efficacy for B-ALL. Further evaluations in larger clinical studies are needed.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Comparative analysis of oral and intravenous iron therapy in rat models of inflammatory anemia and iron deficiency.\r\nv. iron is trapped in macrophages and may enhance inflammation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMaintaining osteoclastogenesis following allogeneic hematopoietic stem cell transplantation for osteopetrosis: evidence from in vitro testing.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlatelet functional abnormalities and clinical presentation in pediatric patients with germline RUNX1, ANKRD26, and ETV6 mutations.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phaseÂ 1, single-arm, open-label, multicenter study in China (LEGEND-2).\r\nThe 4-year follow-up data of LCAR-B38M therapy demonstrated a favorable long-term safety profile and a durable response in patients with RRMM.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLong noncoding RNA Smyca coactivates TGF-ÃŸ/Smad and Myc pathways to drive tumor progression.\r\nThis study uncovers a lncRNA that coordinates tumor-relevant pathways to orchestra a pro-tumor program and establishes the clinical values of Smyca in cancer prognosis and therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    [18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial.\r\n[ 18 F]FDG-PET-CT can support decision making regarding antimicrobial cessation or de-escalation and should be considered in the management of patients with haematological diseases and persistent or recurrent high-risk neutropenic fever after chemotherapy or transplant conditioning. Funding National Health and Medical Research Council Centre of Research Excellence (APP1116876), Melbourne Health foundation, Gilead Research Fellowship grants supported this study.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAssociations between non-anaemic iron deficiency and outcomes following elective cardiac surgery (IDOCS): a prospective cohort study.\r\nRoutine preoperative investigation for iron deficiency in patients without anaemia undergoing elective cardiac surgery using the definitions we tested might be low-value care. Funding Australian and New Zealand College of Anaesthetists Foundation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEnoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.\r\nFutility of the treatment under the initial study design assumptions could not be conclusively assessed owing to under-representation of older patients and consequent low event rates. Funding SNSF (National Research Programme COVID-19 NRP78: 198352), University Hospital Zurich, University of Zurich, Dr-Ing Georg Pollert (Berlin), Johanna DÃ¼rmÃ¼ller-Bol Foundation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.\r\nFunding Jiangsu Hengrui Pharmaceuticals. Translation For the Chinese translation of the abstract see Supplementary Materials section.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.\r\nAlthough the trial was terminated early, our data, combined with data from similar studies, provide further insights to inform international guidelines and influence clinical practice. Funding The Thrombosis Research Institute and Sanofi UK.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.\r\nImportantly, the Dock1/Rac pathway is targetable in Npm1 cA/+ ; Smc3 /+ AMLs. Our results suggest that Dock1/Rac represents a potential target for the treatment of patients harboring NPM1cA and cohesin mutations and supports the use of combinatorial genetics to identify novel precision oncology targets.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEfficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.\r\nAdditionally, the mean difference in percentage maximum reduction in serum tryptase levels was 60.3% greater in the avapritinib cohort (95% CI: -72.8, -47.9;  p<0.001). With no randomized controlled trials comparing avapritinib to BAT, these data offer crucial insights into the improved efficacy of avapritinib for the treatment of AdvSM.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study.\r\nThe DOAC Dipstick sensitively identified effective thrombin and factor Xa inhibition in a real-world cohort of patients presenting at an emergency department. Therefore, the dipstick might provide a valuable test to detect relevant DOAC exposure in emergencies, although further studies will be needed to confirm these findings.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nResumption of Antiplatelet Therapy after Major Bleeding.\r\nShared decision-making involving various disciplines is essential to determine the optimal strategy. The present article addresses clinically relevant questions focusing on the most life-threatening or frequently occurring bleeding events, such as intracranial hemorrhage and gastrointestinal bleeding, and discusses the evidence for antiplatelet therapy resumption using individual risk assessment in high-risk cardiovascular disease patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#eiguohbdev .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#eiguohbdev .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#eiguohbdev .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#eiguohbdev .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#eiguohbdev .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#eiguohbdev .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#eiguohbdev .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#eiguohbdev .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#eiguohbdev .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#eiguohbdev .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#eiguohbdev .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#eiguohbdev .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#eiguohbdev .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#eiguohbdev .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#eiguohbdev .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#eiguohbdev .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#eiguohbdev .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#eiguohbdev .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#eiguohbdev .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#eiguohbdev .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#eiguohbdev .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#eiguohbdev .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#eiguohbdev .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#eiguohbdev .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#eiguohbdev .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#eiguohbdev .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#eiguohbdev .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#eiguohbdev .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#eiguohbdev .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#eiguohbdev .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#eiguohbdev .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#eiguohbdev .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#eiguohbdev .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#eiguohbdev .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#eiguohbdev .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    Immunotherapy in unresectable stage III non-small cell lung cancer: state of the art and novel therapeutic approaches.\r\nradiomics and ctDNA). Identifying distinct subsets of patients to tailor anti-cancer treatment is a priority, especially in a heterogeneous disease such as stage III NSCLC.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Avoiding fratricide: a T-ALL order.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlease eat me! Targeting CD47 and CD38 in T-ALL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRevealing the dark secrets of TP53-mutated AML.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSafety of genetically modified T cells.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe CD19neg needle in the haystack.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.\r\nIn view of the collective data, we advocate treating TME as a complete ecosystem in which components crosstalk with each other to synergistically achieve tumor adaptive changes. Finally, we describe the potential utility of m 6 A methylation-targeted therapies and tumor immunotherapy in clinical applications and the challenges faced, with the aim of advancing m 6 A methylation research.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRecent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy.\r\nGiven the synergistic effect of VEGFR and other therapies in tumor development and progression, VEGFR dual-target inhibitors are becoming an attractive approach due to their favorable pharmacodynamics, low toxicity, and anti-resistant effects. This perspective provides an overview of the development of VEGFR dual-target inhibitors from multiple aspects, including rational target combinations, drug discovery strategies, structure-activity relationships and future directions.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.\r\nWe also evaluate the significance of the STIE, TIME, and their interactions as well as changes after local radiotherapy and systemic immunotherapy or combined immunotherapy. We focus our review on the evidence of lung cancer, hepatocellular carcinoma, and nasopharyngeal carcinoma, aiming to reshape STIE and TIME to enhance immunotherapy efficacy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia.\r\nIn this Viewpoint, we review the retrospective and prospective data supporting both intensive chemotherapy and low-intensity venetoclax-based approaches in older patients with acute myeloid leukaemia. We also discuss our own approach to the management of older or unfit patients with acute myeloid leukaemia, including how cytomolecular features have a role in establishing the optimal front-line therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMyelodysplastic syndrome and autoimmune disorders: two sides of the same coin?\r\nWe note that systemic inflammatory and autoimmune diseases are often steroid-dependent;  however, studies have also evaluated the roles of other immunomodulating therapies. In this Viewpoint, we critically appraise and review the literature on the epidemiology, pathophysiology, and management of systemic inflammatory and autoimmune diseases that are associated with myelodysplastic syndromes and related diseases.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe dystopia of enforced childbirth.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#zzvsmpwtho .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#zzvsmpwtho .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#zzvsmpwtho .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#zzvsmpwtho .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#zzvsmpwtho .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#zzvsmpwtho .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#zzvsmpwtho .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#zzvsmpwtho .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#zzvsmpwtho .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#zzvsmpwtho .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#zzvsmpwtho .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#zzvsmpwtho .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#zzvsmpwtho .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#zzvsmpwtho .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#zzvsmpwtho .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#zzvsmpwtho .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#zzvsmpwtho .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#zzvsmpwtho .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#zzvsmpwtho .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#zzvsmpwtho .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#zzvsmpwtho .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#zzvsmpwtho .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#zzvsmpwtho .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#zzvsmpwtho .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#zzvsmpwtho .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#zzvsmpwtho .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#zzvsmpwtho .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#zzvsmpwtho .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#zzvsmpwtho .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#zzvsmpwtho .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#zzvsmpwtho .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#zzvsmpwtho .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#zzvsmpwtho .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#zzvsmpwtho .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#zzvsmpwtho .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    SF3B1 mutations in primary and secondary myelofibrosis: clinical, molecular and prognostic correlates.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Reply to the Letter to the Editor \"Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?\" by Sasaki, Yasutsuna; Sato, Etuko; Sakaguchi, Chikara.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDifferences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nG-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIntegrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVery late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia.\r\nNotably, CLL-1 is also highly expressed in normal granulocytes, so bridging hematopoietic stem cell transplantation (HSCT) may be a viable strategy to rescue long-term agranulocytosis due to off-target toxicity. In conclusion, this study is the first to demonstrate the positive efficacy and tolerable safety of CLL-1 CAR-T cell therapy in adult R/R AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTransparently report on the process of moving from evidence to recommendation - Authors' reply.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTransparently report on the process of moving from evidence to recommendation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOthers\r\nall remaining publications eg case reports, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#artzgzyslj .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#artzgzyslj .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#artzgzyslj .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#artzgzyslj .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#artzgzyslj .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#artzgzyslj .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#artzgzyslj .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#artzgzyslj .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#artzgzyslj .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#artzgzyslj .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#artzgzyslj .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#artzgzyslj .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#artzgzyslj .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#artzgzyslj .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#artzgzyslj .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#artzgzyslj .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#artzgzyslj .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#artzgzyslj .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#artzgzyslj .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#artzgzyslj .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#artzgzyslj .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#artzgzyslj .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#artzgzyslj .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#artzgzyslj .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#artzgzyslj .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#artzgzyslj .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#artzgzyslj .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#artzgzyslj .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#artzgzyslj .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#artzgzyslj .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#artzgzyslj .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#artzgzyslj .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#artzgzyslj .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#artzgzyslj .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#artzgzyslj .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Nitrous oxide misuse: not a laughing matter.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThrombocytopenia, anasarca, and severe inflammation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    A unique report of breast intravascular NK/T-cell lymphoma mimicking breast carcinoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLonger-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    CD34+-selected stem cell boost can safely improve cytopenias following CAR-T therapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGraft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLoncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRelative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Breast cancer survivors face greater cardiometabolic risks.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNew studies examine COVID-19 risks among cancer patients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Graft-versus-host disease in allogeneic transplantation: the good and the bad.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImages from the Haematologica Atlas of Hematologic Cytology: parvovirus-induced pure red cell aplasia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    [18F]FDG-PET-CT in neutropenic fever: a picture searching for a frame(work).\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAntithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCOVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEasy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFactor IX Padua for haemophilia B gene addition: universal adaptation and repeated success.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFirst, do no harm: the neglect of female genital disease following haematopoietic stem-cell transplantation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIdiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIron deficiency: effects beyond anaemia?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-07-11T14:27:42-04:00",
    "input_file": {}
  },
  {
    "path": "hema/07-01-2022/",
    "title": "Fri Jul 01 2022",
    "description": "80 articles - From Friday Jun 24 2022 to Friday Jul 01 2022",
    "author": [],
    "date": "2022-07-01",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nLetters&Replies\r\nOthers\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#mympktvrwm .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#mympktvrwm .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mympktvrwm .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#mympktvrwm .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#mympktvrwm .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mympktvrwm .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mympktvrwm .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mympktvrwm .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#mympktvrwm .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#mympktvrwm .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#mympktvrwm .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#mympktvrwm .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mympktvrwm .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mympktvrwm .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#mympktvrwm .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#mympktvrwm .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mympktvrwm .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#mympktvrwm .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mympktvrwm .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mympktvrwm .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mympktvrwm .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mympktvrwm .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#mympktvrwm .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mympktvrwm .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mympktvrwm .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mympktvrwm .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mympktvrwm .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mympktvrwm .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#mympktvrwm .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#mympktvrwm .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#mympktvrwm .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#mympktvrwm .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#mympktvrwm .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#mympktvrwm .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#mympktvrwm .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.\r\nUsing a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients\r\nThis conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related critical illness.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.\r\nAdditional issues considered include the role of salvage autologous stem cell transplantation, risk stratification, targeted approaches for genetic subsets of MM, appropriate clinical trial endpoints, and promising investigational agents. This report summarizes the deliberations of the working group and suggests potential avenues of research to improve the precision, timing, and durability of treatments for Myeloma.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#dohmtxaafz .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#dohmtxaafz .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dohmtxaafz .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#dohmtxaafz .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#dohmtxaafz .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#dohmtxaafz .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dohmtxaafz .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#dohmtxaafz .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#dohmtxaafz .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#dohmtxaafz .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#dohmtxaafz .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#dohmtxaafz .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#dohmtxaafz .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#dohmtxaafz .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#dohmtxaafz .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#dohmtxaafz .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#dohmtxaafz .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#dohmtxaafz .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#dohmtxaafz .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#dohmtxaafz .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#dohmtxaafz .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#dohmtxaafz .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#dohmtxaafz .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#dohmtxaafz .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dohmtxaafz .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#dohmtxaafz .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dohmtxaafz .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#dohmtxaafz .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#dohmtxaafz .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#dohmtxaafz .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#dohmtxaafz .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#dohmtxaafz .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#dohmtxaafz .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#dohmtxaafz .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#dohmtxaafz .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#egtoyqmbop .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#egtoyqmbop .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#egtoyqmbop .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#egtoyqmbop .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#egtoyqmbop .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#egtoyqmbop .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#egtoyqmbop .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#egtoyqmbop .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#egtoyqmbop .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#egtoyqmbop .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#egtoyqmbop .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#egtoyqmbop .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#egtoyqmbop .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#egtoyqmbop .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#egtoyqmbop .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#egtoyqmbop .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#egtoyqmbop .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#egtoyqmbop .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#egtoyqmbop .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#egtoyqmbop .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#egtoyqmbop .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#egtoyqmbop .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#egtoyqmbop .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#egtoyqmbop .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#egtoyqmbop .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#egtoyqmbop .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#egtoyqmbop .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#egtoyqmbop .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#egtoyqmbop .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#egtoyqmbop .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#egtoyqmbop .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#egtoyqmbop .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#egtoyqmbop .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#egtoyqmbop .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#egtoyqmbop .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Chronic Myeloid Leukemia: 2022 Update on Diagnosis, Therapy and Monitoring.\r\nAllogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP and failure (due to resistance) of at least 2 TKIs, and for al patients in advanced phase disease. Older patients who have a cytogenetic relapse post failure on al TKIs can maintain long-term survival if they continue a daily most effective/least toxic TKI, with or without the addition of non-TKI anti-CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan, others).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nErythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.\r\nThese results for serum transferrin saturation, hepcidin, ferritin, and erythrocyte indices were consistent with improved iron availability in the patients receiving vadadustat. Thus, overall, vadadustat had beneficial effects on three aspects of erythropoiesis in patients with anemia associated with chronic kidney disease: increased endogenous erythropoietin production, improved iron availability to erythroid cells, and increased reticulocytes in the circulation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy.\r\nWe also provide in vitro data supporting the functionality of HERV-specific CD8 + T-cells against AML cells. These results show that HERVs represent an important source of genetic information that can help enhancing disease stratification or biomarker identification and an important reservoir of alternative tumor-specific T cell epitopes relevant for cancer immunotherapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.\r\nThe results confirm long-term benefit of nivolumab plus low-dose ipilimumab for previously treated patients with MSI-H/dMMR mCRC. The safety profile was manageable with no new safety signals.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.\r\nMice carrying al four genetic lesions showed a greater than 50-fold expansion of spontaneous splenic GCs exhibiting aberrant histologic features with a dark zone immunophenotype and went on to develop DLBCL in the spleen with age. Thus, by combining multiple hallmark genetic alterations associated with MCD, our study identifies aberrant spontaneous splenic GCB as a likely cell-of-origin for this aggressive genetic subtype of lymphoma.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGGCX mutants that impair hemostasis reveal the importance of processivity and full carboxylation to VKD protein function.\r\ng. warfarin therapy or vitamin K deficiency.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLiver to lung microembolic NETs promote Gasdermin-D-dependent inflammatory lung injury in Sickle Cell Disease.\r\nRemarkably, these NETs travel intravascularly from liver to lung, where they promote neutrophil-platelet aggregation and the development of acute lung injury. This study introduces a novel paradigm that liver to lung embolic translocation of NETs promotes pulmonary vascular vaso-occlusion, and identifies a new GSDMD-mediated, P-selectin-independent mechanism of lung injury in SCD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProtein tyrosine phosphatase PTPN22 negatively modulates platelet function and thrombus formation.\r\nFurthermore, inhibition of PTPN22 enhanced human platelet aggregation, spreading, clot retraction and increased PDE5A phosphorylation (Ser92). In conclusion, our study demonstrates a novel role of PTPN22 in platelet function and arterial thrombosis, identifying new potential targets for future prevention of thrombotic or cardiovascular diseases.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPunctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma.\r\nStudy can be found in EudraCT N. 2009-012807-25\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSpecification of hematopoietic stem cells in mammalian embryos: A rare or frequent event?\r\nHere, we explore recent advances in understanding the numbers and kinetics of cells that emerge during development to support lifelong hematopoiesis-advances that are made possible by new technologies allowing interrogation of lifelong blood potential without embryo perturbation or transplantation. Illuminating the dynamics of these cells during normal development informs efforts to better understand the origins of hematologic disease and engineer HSCs from differentiating pluripotent stem cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSTAT1 is essential for HSC function and maintains MHCIIhi stem cells that resists myeloablation and neoplastic expansion.\r\nSimilar to mice, high MHCII expression is a feature of human HSCs residing in a deeper quiescent state. Our results therefore position STAT1 at the interface of stem cell heterogeneity and the interplay between stem cells and the adaptive immune system, areas of broad interest in the wider stem cell field.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTargeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis.\r\nRadiotherapy remains an important component of treatment for patients who are SER. Trial Registration: Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients with Newly Diagnosed Hodgkin's' Lymphoma;  NCT00302003.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nWhole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPN.\r\nWe found that N-glycosylation inhibition significantly reduced CFU-MK formation in patient-derived CALR-mutant bone marrow, as compared to bone marrow-derived from healthy donors. In aggregate, our findings advance the development of clonally selective treatments for CALR-mutant MPN.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies.\r\nTreatment of mice expressing human FcRIIA with scIV.3-IdeS reduced thrombocytopenia in a model of ITP and significantly improved the half-life of transfused platelets expressing human FcRIIA. Together, these data suggest that scIV.3-IdeS can selectively remove pathogenic antiplatelet IgG and may be a potential treatment for patients with ITP and severe bleeding.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCOVID-19 and Venous Thromboembolism Risk in Patients With Sickle Cell Disease.\r\nAfter adjusting for differences in baseline characteristics, no significant differences in VTE rates within 6 months were found between the two groups (adjusted-RR=1.06 (95% Confidence Interval: 0.79-1.41)). These data suggest that hospitalization with COVID-19 does not further increase VTE risk in patients with SCD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDefective VWF secretion due to the expression of MYH9-RD E1841K mutant in endothelial cells disrupts hemostasis.\r\nFinally, we present mechanistic findings that E1841K mutation not only interferes with S1943 phosphorylation and impairs the peripheral distribution of Rab27a positive WPBs in ECs under quiescent condition, but also interferes with S1916 phosphorylation by disrupting the interaction with zyxin and CKIIa, and reduces actin framework formation around WPBs and subsequent VWF secretion under the stimulation by a cAMP agonist. Altogether, our results suggest that impaired cAMP-induced endothelial VWF secretion by E1841K mutant expression may contribute to the MYH9-RD bleeding phenotype.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDevelopment of a Carotid Artery Thrombolysis (iCAT) Stroke Model in Mice.\r\nThese studies confirm the benefits of anticoagulants in enhancing thrombolysis and large artery recanalization, however at high levels of anticoagulation (~3-fold prolongation of APTT), this effect is offset by increased incidence of carotid artery embolization and distal middle cerebral artery occlusion. The iCAT stroke model should provide important new insight into the effects of adjunctive antithrombotic agents on real-time thrombus dynamics during thrombolysis, and their correlation with stroke outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImprovement of Hemolytic Anemia with GBT1118 is Reno-protective in Transgenic Sickle Mice.\r\nThis study provides mechanistic insights into potential reno-protective effects of strategies which mitigate hemolysis in SCA. Studies in humans are needed to confirm our findings.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImprovements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades.\r\nAllo-HCT outcomes for adults with ALL have improved over the past 30 years. Improved outcomes in the future will require more effective prevention of relapse in patients with ALL not in CR1 and in those with high-risk chromosomal abnormalities.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMetabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells.\r\nCorrelations between gas-handling and lipidomic changes were modest. Thus, hypoxic storage of RBCs preserves key metabolic pathways and O2 exchange properties, thereby improving the functional quality of blood products and potentially influencing transfusion outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcomes of elderly diffuse large B-cell lymphoma patients treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.\r\nProgression/relapse led to poor prognosis after second-line chemotherapy in the pre-CAR-T era. Novel approaches in first-line and alternative treatments in second-line treatments are warranted in this population.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPhase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.\r\nGiven the favorable toxicity profile, an important advantage for the typically frail AL population, further evaluation of the ixazomib in other combinations in the upfront setting is warranted. This trial is registered at as NCT01864018.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRefining the migration and engraftment of short-term and long-term HSCs by enhancing homing-specific adhesion mechanisms.\r\nRemarkably, fucosylation of Flk2negCD34pos ST-HSCs consistently led to their ability to transplant secondary recipients, the gold standard for testing functionality of LT-HSCs. These data suggest that treatments to overcome the molecular disparity in adhesion mechanisms among ST-HSCs and LT-HSCs, differentially influences their abilities to migrate and engraft in vivo and boosts ST-HSCs engraftment in vivo.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRomiplostim addition to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels.\r\nWe thus tested if the addition of Romiplostim to the clinically applied conditioning chemotherapy regimen cyclophosphamide and busulfan leads to increased efficacy of the chemotherapeutic regimen. We found that Romiplostim not only sensitizes HSCs to chemotherapy but also enables a reduction of the main chemotherapeutic component Busulfan by half, while HSC engraftment levels are maintained in long-term, serial transplantation assays.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.\r\nOf therapeutic relevance, we validated our results by immunohistochemistry, identifying a subset of TCF1+ progenitor exhausted T-cells enriched in THRLBCL patients. This subset of TCF1+ exhausted T-cells correlates with good clinical response to immune checkpoint therapy and may improve prediction of anti-PD-1 response in THRLBCL patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    A multiparametric niche-like drug screening platform in acute myeloid leukemia.\r\nIn this cohort, a 23-drug screen nominated ruxolitinib as a sensitizer to anthracycline-cytarabine. This finding was validated in an NPM1c PDX model.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nNovel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.\r\nGC007F demonstrated superior expansion capacity and a less exhausted phenotype as compared to (C-CAR-T) cells. Moreover, this first-in-human clinical study showed that the novel, next-day manufacturing FasTCAR-T cells was feasible with a manageable toxicity profile in patients with R/R B-ALL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nCA Cancer J Clin\r\n    Cancer treatment and survivorship statistics, 2022.\r\nCA Cancer J Clin. 2022; 72:000-000.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.\r\nNone of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs 73%, p=0.003, and 42% vs 16%, p.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinical features of hepatitis E infections in patients with hematological disorders.\r\nNevertheless, since mortality from the progression of hematological disease was higher than hepatitis E-related mortality, we suggest a careful case-by-case decision of cancer-treatment modification. Patients in post-treatment follow-up phase may also suffer from severe courses and hepatitis E chronification occurs as frequently as in patients undergoing active therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCombination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk between NK cells, monocytes and myeloma cells.\r\nIn conclusion, our findings suggest that MM patients require Elo and Len-mediated upregulation of CD54 on the autologous myeloma cells, in combination with NK cells and monocytes to mediate an effective anti-tumour response. Further, our data suggest that increased myeloma cell CD54 expression levels could be a powerful predictive biomarker for response to Elo and Len treatment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nComparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling.\r\nWe confirm significant mortality risk within the first 100 days for allo-first and suggest that tandem transplant strategies are superior. Disease status at time of transplant influences outcome, this knowledge may help guide clinical decisions on transplant strategy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDouble punch for plasma cell leukemia.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIgM monoclonal gammopathies of clinical significance: diagnosis and management.\r\nA multidisciplinary approach is required particularly for IgM-related neuropathies and Schnitzler syndrome. Future work exploring novel clone directed agents and pathogenetic IgM-directed therapies is welcomed.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMolecular predictors of response to venetoclax plus hypomethylating agent in treatment-naÃ¯ve acute myeloid leukemia.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMyeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA matched and haploidentical transplantation: results of a phase II study.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlasma cell leukemia: another piece of the puzzle.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRoutine clinical parameters and laboratory testing predict therapy related myeloid neoplasms after treatment for breast cancer.\r\nOf the 206 BC patients who underwent BMBx included in our study, 107 had t-MN. By multivariable analysis, white blood cell count 4-11 K/mcL, absolute neutrophil count (ANC) /1.5 K/mcL, hemoglobin h12.2 g/dL, red cell distribution width 11.5-14.5%, the presence of bone metastasis and a time from BC diagnosis to BMBx.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms.\r\nThis finding also correlated with increased clonogenic potential after serial replating in the setting of H -induced DNA damage and activation of error-prone DNA repair may result in secondary genetic damage potentially predisposing to leukemia leukemic evolution. In conclusion, our study for the first time demonstrates that germline MPO variants may constitute risk alleles for MN evolution.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency.\r\nThe nucleotide-level resolution achieved for al SVs allowed breakpoint analysis, which revealed repetitive elements and microhomologies supporting a common replication-based mechanism for al the SVs. Our study underscores the utility of long-read sequencing technology as a complementary method to identify, characterize, and unveil the molecular mechanism of disease-causing SVs involved in ATD, and enlarges the catalogue of genetic disorders caused by retrotransposon insertions.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTreatment and bleeding complications of cancer-associated venous thromboembolism: A Korean population-based study.\r\nDOACs have become the most prescribed anticoagulant in CAT. Bleeding was more prevalent with DOAC than PAC. The bleeding complications should be carefully monitored to ensure optimal treatment, especially with DOAC.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#fqyynaokuh .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#fqyynaokuh .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fqyynaokuh .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#fqyynaokuh .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#fqyynaokuh .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fqyynaokuh .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fqyynaokuh .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fqyynaokuh .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#fqyynaokuh .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#fqyynaokuh .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#fqyynaokuh .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#fqyynaokuh .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fqyynaokuh .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fqyynaokuh .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#fqyynaokuh .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#fqyynaokuh .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fqyynaokuh .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#fqyynaokuh .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fqyynaokuh .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fqyynaokuh .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fqyynaokuh .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fqyynaokuh .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#fqyynaokuh .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fqyynaokuh .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fqyynaokuh .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fqyynaokuh .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fqyynaokuh .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fqyynaokuh .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#fqyynaokuh .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#fqyynaokuh .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#fqyynaokuh .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#fqyynaokuh .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#fqyynaokuh .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#fqyynaokuh .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#fqyynaokuh .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    The deleterious effect of acetaminophen in cancer immunotherapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    A tale of two alleles: TP53 and transformation in MPNs.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCAR T-cell therapy: which product for which patient?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCeramide: improving Bcl-2 inhibitor therapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHighjacking myeloma's niche with beefed-up CAR-Ts.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMechanisms of resistance to mogamulizumab.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPain without gain: steroids and sickle crisis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPhagocytosing with TP53 and extracellular vesicles.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSmart salvage treatment for Hodgkin lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nZinc: a damage signal promoting thymic repair.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.\r\nFinally, we devote a section to the study of exosomes as diagnostic and prognostic tools in clinical courses that is important for the treatment of cancer patients. This review provides a comprehensive understanding of the role of exosomes in cancer therapy, focusing on their therapeutic value in cancer progression and remodeling of the tumor microenvironment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#lyazgeoyga .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#lyazgeoyga .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lyazgeoyga .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#lyazgeoyga .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#lyazgeoyga .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lyazgeoyga .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lyazgeoyga .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lyazgeoyga .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#lyazgeoyga .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#lyazgeoyga .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#lyazgeoyga .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#lyazgeoyga .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lyazgeoyga .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lyazgeoyga .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#lyazgeoyga .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#lyazgeoyga .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lyazgeoyga .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#lyazgeoyga .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lyazgeoyga .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lyazgeoyga .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lyazgeoyga .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lyazgeoyga .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#lyazgeoyga .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lyazgeoyga .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lyazgeoyga .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lyazgeoyga .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lyazgeoyga .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lyazgeoyga .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#lyazgeoyga .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#lyazgeoyga .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#lyazgeoyga .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#lyazgeoyga .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#lyazgeoyga .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#lyazgeoyga .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#lyazgeoyga .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Clinical Features Associated with Thrombotic Events in Children with Myeloproliferative Neoplasms.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nComprehensive assessment of cognitive function in adults with moderate and severe sickle cell disease.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReal-life incidence of thrombotic events in leukemia patients treated with ponatinib.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSingle cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Clinical and therapeutic implications of BRAF fusions in histiocytic disorders.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nHaploidentical vs matched sibling donor transplant for paroxysmal nocturnal haemoglobinuria: A multicenter study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\n\r\n\r\n\r\nOthers\r\nall remaining publications eg case reports, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#sxtwtmljjq .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#sxtwtmljjq .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#sxtwtmljjq .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#sxtwtmljjq .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#sxtwtmljjq .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#sxtwtmljjq .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#sxtwtmljjq .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#sxtwtmljjq .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#sxtwtmljjq .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#sxtwtmljjq .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#sxtwtmljjq .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#sxtwtmljjq .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#sxtwtmljjq .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#sxtwtmljjq .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#sxtwtmljjq .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#sxtwtmljjq .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#sxtwtmljjq .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#sxtwtmljjq .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#sxtwtmljjq .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#sxtwtmljjq .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#sxtwtmljjq .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#sxtwtmljjq .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#sxtwtmljjq .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#sxtwtmljjq .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#sxtwtmljjq .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#sxtwtmljjq .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#sxtwtmljjq .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#sxtwtmljjq .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#sxtwtmljjq .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#sxtwtmljjq .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#sxtwtmljjq .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#sxtwtmljjq .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#sxtwtmljjq .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#sxtwtmljjq .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#sxtwtmljjq .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    Al-Sawaf O, Lilienweiss E, Bahlo J, etÂ al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020;135(11):866-870.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDysplastic megakaryocytes in dyskeratosis congenita with variant in PARN.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFarley A, Lloyd S, Dayton M, Biben C, Stonehouse O, Taoudi S. Severe thrombocytopenia is sufficient for fetal and neonatal intracerebral hemorrhage to occur. Blood. 2021;138(10):885-897.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIntroduction to a review series on pediatric hematology.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLiu Y, Chen Q, Jeong H-W, etÂ al. Dopamine signaling regulates hematopoietic stem and progenitor cell function. Blood. 2021;138(21):2051-2065.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlasma cell leukemia with small cell morphology.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUnexpected presentation of cold agglutinin syndrome with B-acute lymphoblastic leukemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEmerging Clinical Trial Designs May Accelerate Translation in Hematology: Lessons from COVID-19.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRevision of RUNX1 Variant Curation Rules.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRR6 prognostic model provides information about survival in myelofibrosis treated with ruxolitinib: validation in a real-life cohort.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVenetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLancet Haematol\r\n    European Hematology Association Hybrid Congress 2022.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-07-01T17:40:18-04:00",
    "input_file": {}
  },
  {
    "path": "hema/06-24-2022/",
    "title": "Fri Jun 24 2022",
    "description": "90 articles - From Friday Jun 17 2022 to Friday Jun 24 2022",
    "author": [],
    "date": "2022-06-24",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nLetters&Replies\r\nOthers\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#lxljlfjuxi .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#lxljlfjuxi .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lxljlfjuxi .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#lxljlfjuxi .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#lxljlfjuxi .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lxljlfjuxi .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lxljlfjuxi .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lxljlfjuxi .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#lxljlfjuxi .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#lxljlfjuxi .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#lxljlfjuxi .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#lxljlfjuxi .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lxljlfjuxi .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lxljlfjuxi .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#lxljlfjuxi .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#lxljlfjuxi .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lxljlfjuxi .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#lxljlfjuxi .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lxljlfjuxi .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lxljlfjuxi .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lxljlfjuxi .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lxljlfjuxi .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#lxljlfjuxi .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lxljlfjuxi .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lxljlfjuxi .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lxljlfjuxi .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lxljlfjuxi .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lxljlfjuxi .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#lxljlfjuxi .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#lxljlfjuxi .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#lxljlfjuxi .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#lxljlfjuxi .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#lxljlfjuxi .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#lxljlfjuxi .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#lxljlfjuxi .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    CA Cancer J Clin\r\n    An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.\r\nCA Cancer J Clin. 2022; 72:000-000.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#pnpvresbvt .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#pnpvresbvt .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pnpvresbvt .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#pnpvresbvt .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#pnpvresbvt .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#pnpvresbvt .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pnpvresbvt .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#pnpvresbvt .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#pnpvresbvt .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#pnpvresbvt .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#pnpvresbvt .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#pnpvresbvt .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#pnpvresbvt .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#pnpvresbvt .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#pnpvresbvt .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#pnpvresbvt .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#pnpvresbvt .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#pnpvresbvt .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#pnpvresbvt .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#pnpvresbvt .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#pnpvresbvt .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#pnpvresbvt .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#pnpvresbvt .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#pnpvresbvt .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pnpvresbvt .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#pnpvresbvt .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pnpvresbvt .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#pnpvresbvt .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#pnpvresbvt .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#pnpvresbvt .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#pnpvresbvt .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#pnpvresbvt .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#pnpvresbvt .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#pnpvresbvt .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#pnpvresbvt .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood Adv\r\n    Direct Oral Anticoagulants in Sickle Cell Disease: A Systematic Review and Meta-Analysis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Systematic Review and Meta-Analysis of Thromboprophylaxis with Heparins Following Intracerebral Hemorrhage.\r\n  Thromboprophylaxis was effective in preventing DVT and PE without increasing the risk of hematoma expansion or bleeding among ICH patients. Future studies should explore the long-term effects of thromboprophylaxis in this population, particularly on the functional outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#brvpfoxoxx .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#brvpfoxoxx .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#brvpfoxoxx .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#brvpfoxoxx .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#brvpfoxoxx .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#brvpfoxoxx .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#brvpfoxoxx .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#brvpfoxoxx .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#brvpfoxoxx .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#brvpfoxoxx .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#brvpfoxoxx .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#brvpfoxoxx .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#brvpfoxoxx .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#brvpfoxoxx .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#brvpfoxoxx .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#brvpfoxoxx .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#brvpfoxoxx .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#brvpfoxoxx .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#brvpfoxoxx .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#brvpfoxoxx .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#brvpfoxoxx .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#brvpfoxoxx .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#brvpfoxoxx .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#brvpfoxoxx .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#brvpfoxoxx .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#brvpfoxoxx .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#brvpfoxoxx .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#brvpfoxoxx .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#brvpfoxoxx .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#brvpfoxoxx .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#brvpfoxoxx .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#brvpfoxoxx .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#brvpfoxoxx .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#brvpfoxoxx .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#brvpfoxoxx .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    A genomic-augmented multivariate prognostic model for the survival of Natural-killer/T-cell lymphoma patients from an international cohort.\r\nWhen we assign an additional risk-score to samples, which are mutant for the GPM, the Harrell's C-indices of GPM-augmented IPI, PINK and PINK-E improved significantly (P<0.001,  2 test) for both PFS and OS. Thus, we report on how genomic mutational information could steer towards better prognostication of NKTCL patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10-4 and Higher.\r\nThis study is registered at as #NCT02458014. Funding provided by Amgen Inc.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nChromosome 1q21 Aberrations Identify Ultra High-Risk Myeloma with Prognostic and Clinical Implications.\r\nWe further validated our findings in an independent cohort of 272 patients. In conclusion, presence of +1q21 is associated with more advanced disease, inferior PFS and OS but especially patients with R-ISS-3 disease and +1q21 have a very poor outcome comprising an ultra-high-risk group.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003-2018).\r\nPlatelet count 60Y, and treatment without Rituximab were poor prognostic factors. Further research is necessary to identify novel therapies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImpact of Autologous Hematopoietic Cell Transplantation on Disease Burden Quantified by Next-Generation Sequencing in Multiple Myeloma Treated with Quadruplet Therapy.\r\nForty per cent achieved MRD reduction in MRD burden with AHCT. Serial NGS MRD demonstrates the incremental effect of AHCT in MM marrow burden in the context of quadruplet induction, particularly in high risk MM.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPredictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: a 25-year longitudinal study.\r\nThe 100-day treatment-related mortality rate was 3% in the latest treatment period (2012-2021), and the 25-year risk of t-MDS/AML was 3%. We conclude that HDM/SCT induces durable hematologic responses and prolonged survival with improved safety in selected patients with AL amyloidosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.\r\nSubstantial disruptions in clinical trial activities were observed early during the pandemic, with a gradual recovery during ensuing time periods, both from an enrollment and an activation standpoint. The observed decline was more prominent among academically sponsored trials, and racial disparities were seen among people taken off trial.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSingle-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.\r\nMM has poor prognosis. Treatment efficacy of anti-PD1+/-ipilimumab was similar and did not differ by ethnicity/race. Naso-oral primaries had numerically higher response to anti-PD1/ipilimumab, without difference in survival. The addition of ipilimumab did not show greater benefit over anti-PD1 for other primary sites. In responders, mDOR was short and acquired resistance was common. Other factors, including site and number of metastases were associated with survival.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.\r\nThe mutant SF3B1 spliceosome depends upon an exonic splicing enhancer within EVI1 exon 13 to promote usage of a cryptic branch point and aberrant 3' splice site within intron 12 resulting in the generation of this isoform. These data provide a mechanistic basis for the frequent co-occurrence of SF3B1 mutations as well as new insights into the pathogenesis of myeloid leukemias harboring inv(3)/t(3; 3).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDeregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.\r\nA compound screen revealed TRAIL-mediated apoptosis as a target to overcome BAX deficiency. Furthermore, antibody or CAR T cells eliminated venetoclax resistant lymphoma cells, paving a clinically applicable way to overcome venetoclax resistance.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEnasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.\r\nThe primary study endpoint was not met but OS was confounded by early dropout and subsequent AML-directed therapies. Enasidenib provided meaningful benefits in EFS, TTF, ORR, HI, and RBC-TI in this heavily pretreated older mutant-IDH2 R/R AML population.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLiver to lung microembolic NETs promote Gasdermin-D-dependent inflammatory lung injury in Sickle Cell Disease.\r\nRemarkably, these NETs travel intravascularly from liver to lung, where they promote neutrophil-platelet aggregation and the development of acute lung injury. This study introduces a novel paradigm that liver to lung embolic translocation of NETs promotes pulmonary vascular vaso-occlusion, and identifies a new GSDMD-mediated, P-selectin-independent mechanism of lung injury in SCD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMacaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions.\r\nThe model was used to test the impact of IL-6 blockage by tocilizumab, documenting a slowing of TET2 mutated expansion, suggesting that interruption of the IL-6 axis may remove the selective advantage of mutant HSPCs. These findings provide a model for examining the pathophysiology of CH and give insights into potential therapeutic interventions.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPunctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma.\r\nStudy can be found in EudraCT N. 2009-012807-25\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSingle-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy.\r\nOur studies reveal the extent of plasticity of CLL cells in their ability to evade venetoclax-induced apoptosis. Importantly, these findings pinpoint new approaches to circumvent venetoclax resistance and provide a specific biological justification for the strategy of venetoclax discontinuation once maximal response is achieved rather than maintaining long-term selective pressure with the drug.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSpecification of hematopoietic stem cells in mammalian embryos: A rare or frequent event?\r\nHere, we explore recent advances in understanding the numbers and kinetics of cells that emerge during development to support lifelong hematopoiesis-advances that are made possible by new technologies allowing interrogation of lifelong blood potential without embryo perturbation or transplantation. Illuminating the dynamics of these cells during normal development informs efforts to better understand the origins of hematologic disease and engineer HSCs from differentiating pluripotent stem cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTET2-mutant clonal hematopoiesis and risk of gout.\r\nThese studies show that TET2-mutant CHIP is associated with an increased risk of gout in humans and that MSU crystals lead to elevated IL-1B levels in Tet2 knockout murine models. We identify CHIP as an amplifier of NLRP3-dependent inflammatory responses to MSU crystals in gout patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe oral ferroportin inhibitor vamifeport improved hemodynamics in a mouse model of sickle cell disease.\r\nAccordingly, intravital video microscopy of fluorescently labeled blood cells in the microvasculature of Townes mice treated with vamifeport demonstrated diminished adhesion to the endothelium and improved hemodynamics. These preclinical data provide a strong proof-of-concept for vamifeport in the Townes model of SCD and support further development of this compound as a potential novel therapy in SCD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies.\r\nTreatment of mice expressing human FcRIIA with scIV.3-IdeS reduced thrombocytopenia in a model of ITP and significantly improved the half-life of transfused platelets expressing human FcRIIA. Together, these data suggest that scIV.3-IdeS can selectively remove pathogenic antiplatelet IgG and may be a potential treatment for patients with ITP and severe bleeding.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCD58 loss in tumor cells confers functional impairment of CAR T cells.\r\nWe found that disruption of CD58 in tumor cells induced the formation of suboptimal immunological synapse (IS) with CAR T cells, which conferred functional impairment of CAR T cells, including the attenuation of cell expansion, degranulation, cytokine secretion and cytotoxicity. In summary, we describe a potential mechanism of tumor intrinsic resistance to CAR T-cell therapy and suggest that this mechanism may be leveraged for developing therapeutic strategies to overcome resistance to CAR T-cell therapy in B-cell malignancies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCPT2 K79 Acetylation Regulates Platelet Lifespan.\r\nBlocking LCACs generation with the inhibitors of AMPK or CPT1, the agonists of Sirt3, and antioxidants tremendously retarded platelet storage lesion in vitro and prolong the survival of stored platelets in vivo post transfusion by single or combined use. In short, we discovered that CPT2 acetylation attenuates fatty acid oxidation and exacerbates platelet storage lesion and may serve as a new target for improving platelet storage quality.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nD-Dimer and Risk for Thrombosis in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia.\r\nIn conclusion, D-dimer levels at ALL diagnosis are associated with venous or arterial thrombosis at 100 days. Future studies should include D-dimer collated with other known risk factors to build a risk assessment model for thrombosis in patients with newly diagnosed ALL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImprovements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades.\r\nAllo-HCT outcomes for adults with ALL have improved over the past 30 years. Improved outcomes in the future will require more effective prevention of relapse in patients with ALL not in CR1 and in those with high-risk chromosomal abnormalities.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMetabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells.\r\nCorrelations between gas-handling and lipidomic changes were modest. Thus, hypoxic storage of RBCs preserves key metabolic pathways and O2 exchange properties, thereby improving the functional quality of blood products and potentially influencing transfusion outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNon-canonical Sonic Hedgehog signaling amplifies platelet reactivity and thrombogenicity.\r\nIn consistence, inhibition of Shh pathway significantly impaired arterial thrombosis in mice. Taken together, above observations strongly support a feed-forward loop of platelet stimulation triggered locally by Shh, similar to ADP and thromboxane A2, that contributes significantly to stability of occlusive arterial thrombus and that can be investigated as potential therapeutic target in thrombotic disorders.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum.\r\nThese variables were also detected as independent adverse prognostic factors for OS in OM-CMML. These data support the consideration of OM-CMML as the first evolutionary stage within the proliferative continuum of CMML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcomes of elderly diffuse large B-cell lymphoma patients treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.\r\nProgression/relapse led to poor prognosis after second-line chemotherapy in the pre-CAR-T era. Novel approaches in first-line and alternative treatments in second-line treatments are warranted in this population.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast percentage AML.\r\n(ClinicalTrials. gov, NCT03268954).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPhase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.\r\nGiven the favorable toxicity profile, an important advantage for the typically frail AL population, further evaluation of the ixazomib in other combinations in the upfront setting is warranted. This trial is registered at as NCT01864018.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReal-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.\r\nIn multivariate analysis, CD8 TN/SCM proportion and International Prognostic Index (IPI) at the time of apheresis were independent risk factors for early progression. Our data show that an easy characterization by flow cytometry of the T-cell phenotype at the time of decision to use commercial CAR-T cells can help to better select patients who will respond.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRomiplostim addition to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels.\r\nWe thus tested if the addition of Romiplostim to the clinically applied conditioning chemotherapy regimen cyclophosphamide and busulfan leads to increased efficacy of the chemotherapeutic regimen. We found that Romiplostim not only sensitizes HSCs to chemotherapy but also enables a reduction of the main chemotherapeutic component Busulfan by half, while HSC engraftment levels are maintained in long-term, serial transplantation assays.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTraumatic vessel injuries initiating hemostasis generate high shear conditions.\r\nThis phenomenon could be explained by the low hydrodynamic resistance of the injuries as compared to that of the downstream vessel network. These findings show that high shear rates are relevant to hemostasis and not exclusive to arterial thrombosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Cancer treatment and survivorship statistics, 2022.\r\nCA Cancer J Clin. 2022; 72:000-000.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low or intermediate-1 risk myelodysplastic syndrome.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCOVID-19 vaccine-induced adverse events predict immunogenicity among recipients of allogeneic haematopoietic stem cell transplantation.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDaunorubicin-60 vs daunorubicin-90 vs idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImmune thrombocytopenia (ITP): diagnosis including secondary ITP, and selection of second line treatment\r\nFinally, there is a short section on refractory disease drawn from our extensive review in Blood in February 2020(1). The clinical nature of the discussions replete with figures and tables and with interspersion of pearls regarding efficacy and toxicity at different ages and genders, will serve the reader in management of \"typical\" adult patients who develop persistent and chronic ITP.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImpaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia.\r\nThese findings reveal that impaired MDSCs are involved in the immunopathogenesis of AA. Pharmacologically targeting of MDSCs by rapamycin might provide a promising therapeutic strategy for AA.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIn-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.\r\nLastly, we show that ctDNA is suitable for the detection of ancestral mutations but may miss a significant proportion of private mutations that can be detected in tissue. Our study clearly shows the existence of intricate patterns of regional and anatomical evolution that can only be disentangled through multi-regional tumor tissue profiling.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMonomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.\r\nMultivariate analysis found a strong negative impact on outcome of MYC expression, TP53 mutation, STAT5B mutation and poor performance status while aberrant B-cell marker expression (20% of cases) correlated with better survival. In conclusion, MEITL is an aggressive disease with resistance to conventional therapy, predominantly characterized by driver gene alterations deregulating histone methylation and JAK/STAT signalling and encompasses genetic and morphologic variants associated with very high clinical risk.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.\r\nWe demonstrate the feasibility of ML for risk stratification in AML as a model disease for hematologic neoplasms using a scalable and reusable ML framework. Our study illustrates the clinical applicability of ML as a decision support system in hematology.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrimary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: Subgroup analyses from ICARIA-MM and IKEMA.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSTAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of BCL2 and BCLXL following glucocorticoid treatment.\r\nThis explains why isolated STAT5 activation does not directly impair the steroid response. Our study suggests that STAT5 activation only contributes to steroid resistance in combination with cellular defects or alternative signaling routes that disable the pro-apoptotic and steroid-induced BIM response.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSurprise, surprise: STAT5 not enough to stop the steroids.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    DNA Methylation and Ischemic Stroke Risk: An Epigenome-Wide Association Study.\r\n  Specific DNA methylation pattern is causally associated with IS risk. These results could be useful for specifically predicting stroke occurrence and could potentially be evaluated as therapeutic targets.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nN-Glycosylation Deficiency Reduces the Activation of Protein C and Disrupts the Endothelial Barrier Integrity.\r\nHowever, pretreatment of cells with APC before thrombin simulation was still associated with a barrier-protecting effect. Taken as a whole, our results show that the partial loss of PMM2 in hCMEC/D3 cells is associated with impaired activation of protein C and a relative increase in barrier permeability.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRisk Factors of Cardiovascular Death after Venous Thromboembolism: Results from a Prospective Cohort Study.\r\n  Risk factors of CVDT after VTE include some traditional cardiovascular risk factors and other risk factors that are related to characteristics of VTE, and patients' comorbidities.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#caxrvpbclk .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#caxrvpbclk .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#caxrvpbclk .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#caxrvpbclk .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#caxrvpbclk .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#caxrvpbclk .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#caxrvpbclk .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#caxrvpbclk .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#caxrvpbclk .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#caxrvpbclk .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#caxrvpbclk .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#caxrvpbclk .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#caxrvpbclk .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#caxrvpbclk .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#caxrvpbclk .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#caxrvpbclk .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#caxrvpbclk .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#caxrvpbclk .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#caxrvpbclk .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#caxrvpbclk .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#caxrvpbclk .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#caxrvpbclk .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#caxrvpbclk .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#caxrvpbclk .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#caxrvpbclk .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#caxrvpbclk .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#caxrvpbclk .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#caxrvpbclk .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#caxrvpbclk .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#caxrvpbclk .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#caxrvpbclk .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#caxrvpbclk .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#caxrvpbclk .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#caxrvpbclk .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#caxrvpbclk .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    A tale of two alleles: TP53 and transformation in MPNs.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHelping GATA1 make complex decisions.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHLH treatment: smarter, not harder.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPhagocytosing with TP53 and extracellular vesicles.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nShining a light on thrombin activation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSmart salvage treatment for Hodgkin lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTransplant in older adults with AML: genomic wheat and chaff.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nWhy B(-)other? About the gap of unknowns in ALL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nZinc: a damage signal promoting thymic repair.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Examining the interrelationships between mindfulness-based interventions, depression, inflammation, and cancer survival.\r\nThere are limited data on the long-term effects of mindfulness on depression and inflammatory markers in patients with cancer, and there are potential barriers to the implementation of mindfulness-based interventions as part of a comprehensive treatment plan. Therefore, it is necessary to further explore these questions through longitudinal studies to establish a survival correlation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.\r\nBesides listing the entities of the classification, we highlight and explain changes from the revised 4 th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5 th edition of the WHO classification of tumours of al organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂ Neoplasms.\r\nWhile a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe WHO Classification of Haematolymphoid Tumours.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.\r\nIn addition, deregulation of the B-cell lymphoma-2 (BCL-2) family proteins BCL-2, B-cell lymphoma-extra large (BCL-X or MCL-1, and the recent (clinical) progress in the development of inhibitors for these BCL-2 family members, followed by the transcriptional and (post-)translational (dys)regulation of the BCL-2 family proteins, including the role of the lymphoid organ microenvironment. Based upon these insights, we discuss how rational combinations of venetoclax with other therapies can be exploited to prevent or overcome venetoclax resistance and improve MCL patient outcome.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#rqinmudxrt .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#rqinmudxrt .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rqinmudxrt .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#rqinmudxrt .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#rqinmudxrt .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rqinmudxrt .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rqinmudxrt .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rqinmudxrt .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#rqinmudxrt .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#rqinmudxrt .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#rqinmudxrt .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#rqinmudxrt .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rqinmudxrt .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rqinmudxrt .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#rqinmudxrt .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#rqinmudxrt .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rqinmudxrt .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#rqinmudxrt .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rqinmudxrt .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rqinmudxrt .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rqinmudxrt .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rqinmudxrt .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#rqinmudxrt .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rqinmudxrt .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rqinmudxrt .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rqinmudxrt .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rqinmudxrt .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rqinmudxrt .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#rqinmudxrt .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#rqinmudxrt .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#rqinmudxrt .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#rqinmudxrt .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#rqinmudxrt .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#rqinmudxrt .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#rqinmudxrt .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Jugular vein inserted central venous catheters (CVC) and the risk of CVC-related bloodstream infections in patients with hematological malignancies.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrevalence of monoclonal gammopathy of undetermined significance (MGUS) in US Black women.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: a population-based cohort study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIn the phase 3 IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.\r\nIn addition, seroconversion was significantly higher in patients with BCMA-based CAR-T than those with CD19-based CAR-T. Thus, an adapted vaccination strategy for HSCT and CAR-T recipients may be required, and further research on the effect of a booster dose of COVID-19 vaccine and the role of cellular response after vaccination is warranted.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe regulation of insulin receptor/insulin-like growth factor 1 receptor ratio, an important factor for breast cancer prognosis, by TRIP-Br1.\r\nTRIP-Br1-mediated higher IR/IGF1R ratio enhanced the proliferation and survival of breast cancer cells. In conclusion, current study may provide an important information in the regulatory mechanism of how breast cancer cells have acquired higher IR/IGF1R ratio.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOthers\r\nall remaining publications eg case reports, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#fcuunbufki .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#fcuunbufki .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fcuunbufki .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#fcuunbufki .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#fcuunbufki .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fcuunbufki .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fcuunbufki .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fcuunbufki .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#fcuunbufki .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#fcuunbufki .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#fcuunbufki .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#fcuunbufki .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fcuunbufki .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fcuunbufki .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#fcuunbufki .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#fcuunbufki .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fcuunbufki .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#fcuunbufki .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fcuunbufki .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fcuunbufki .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fcuunbufki .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fcuunbufki .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#fcuunbufki .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fcuunbufki .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fcuunbufki .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fcuunbufki .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fcuunbufki .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fcuunbufki .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#fcuunbufki .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#fcuunbufki .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#fcuunbufki .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#fcuunbufki .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#fcuunbufki .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#fcuunbufki .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#fcuunbufki .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Neutrophil-Erythrocyte Rosettes in COVID-19.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Al-Sawaf O, Lilienweiss E, Bahlo J, etÂ al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020;135(11):866-870.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFarley A, Lloyd S, Dayton M, Biben C, Stonehouse O, Taoudi S. Severe thrombocytopenia is sufficient for fetal and neonatal intracerebral hemorrhage to occur. Blood. 2021;138(10):885-897.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFlorid reactive follicular hyperplasia with exuberant HHV8 infection.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenetics and outcome in older AML transplant.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLiu Y, Chen Q, Jeong H-W, etÂ al. Dopamine signaling regulates hematopoietic stem and progenitor cell function. Blood. 2021;138(21):2051-2065.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlasma cell leukemia with small cell morphology.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Koh J, Jang I, Mun S, etÂ al. Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv. 2021;5(20):3919-3930.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLissitchkov T, Willemze A, Katragadda S, etÂ al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRR6 prognostic model provides information about survival in myelofibrosis treated with ruxolitinib: validation in a real-life cohort.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRural-urban disparities in place of death in hematologic malignancies in the U.S. 2003-2019.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe extent of residual WT hematopoietic stem and progenitor cells is associated with the degree of anemia in SF3B1-mutated MDS-RS patients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVenetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Unbiased decision-making for acute myeloid leukemia still needed.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    European Hematology Association Hybrid Congress 2022.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNuclear translocation of TFE3 under hypoxia enhances the engraftment of human hematopoietic stem cells.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-06-24T19:16:46-04:00",
    "input_file": {}
  }
]
